Sensei Biotherapeutics Inc

Sensei Biotherapeutics Inc. an immuno-oncology company engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101 SNS-103 and SNS-102 monoclonal antibodies which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals Inc. Sensei Biotherapeutics Inc. was incorporated in 1999 and is headquartered in Rockville Maryland.